Syensqo (SYENS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
21 Jan, 2026Executive summary
Q3 2025 net sales were €1.52 billion, down 7% year-over-year due to lower volumes and adverse FX, but margins and free cash flow remained resilient, supported by cost savings and specialty positioning.
Underlying EBITDA was €326 million, down 13% year-over-year, with margin at 21.5%, up 40 bps sequentially.
Free cash flow reached €250 million, a significant increase from €27 million in Q3 2024, supported by working capital inflows and Edison compensation.
Announced divestment of Oil & Gas business for €135 million (~7x EBITDA), expected to close in Q1 2026, advancing the specialty strategy.
Leadership transition underway, with CEO change announced for 2026.
Financial highlights
Q3 2025 net sales: €1,517 million, down 7.1% year-over-year; gross profit: €484 million, down 15%; gross margin: 31.9%, down 310 bps.
Underlying EBITDA: €326 million, margin 21.5%, down 140 bps year-over-year but up 40 bps sequentially.
Free cash flow: €250 million in Q3; cash conversion (LTM) at 76%, up 690 bps year-over-year.
Net profit attributable to shareholders: €110 million, down 32% year-over-year; basic EPS: €1.08.
Net debt: €2.1 billion; leverage ratio: 1.6x; gearing ratio: 25%.
Outlook and guidance
Full-year 2025 guidance: underlying EBITDA ~€1.25 billion, capex below €600 million, free cash flow ~€325 million.
Outlook revised downward due to slower electronics recovery, FX headwinds, and temporary copper mine closure; cost-saving initiatives targeting >€200 million run-rate savings by end of 2026.
Q4 2025 expected to remain weak with continued inventory destocking and macroeconomic headwinds; electronics and aerospace recovery now expected in 2026.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest growth.SYENS
Q4 202526 Feb 2026 - Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025